BCAB - BioAtla Inc Price-to-Projected Revenue Ratio

BioAtla (BCAB) - corporate logo

Can CAB technology protect tissues from toxicity by creating an insurmountable patent barrier? BioAtla, Inc. (BCAB) is addressing this through flexible international component sourcing to optimize research costs. However, fierce competition with tech giants for licenses maintains certain risks. The company's forward P/S dynamics confirm these trends, with the current level at 0.30, illustrating the balance of the business's market value.

BioAtla Corp - BCAB Projected Price to Revenue (period 07/04/2022 - 09/06/2026)

Comprehensive metric breakdowns and analytics for bioatla.com (BCAB)

- market price and analyst price targets:
Price Chart BioAtla|BCAB - Price Target Chart
- market capitalization statistics:
Market Value BCAB|BCAB - Total Enterprise Value
- book value of equity indicators:
Book Value per Share BioAtla|BCAB - Book Value of Business|Market Cap to Net Assets Ratio bioatla.com|BCAB - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio BioAtla, Inc.|BCAB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio BioAtla|BCAB - Company Cumulative Indebtedness|Debts to Book Capitalization BCAB|BCAB - Company Long-Term Loans and Borrowings|Company Short-Term Debts BioAtla|Quick Liquidity bioatla.com
- financial results and valuation multiples details:
BCAB - Final Profit|Projected Future Earnings BioAtla, Inc.|BCAB - P/E Multiple|Future Price to Earnings BioAtla|BCAB - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio BCAB|BCAB - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) BioAtla|BCAB - Earnings per share for the last twelve months|Quarterly EPS earnings growth bioatla.com|BCAB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year BioAtla, Inc.
- revenue and sales proceeds data:
BCAB - Company Total Revenue|Projected Sales Volume BioAtla|BCAB - P/S Multiple|Forward Price-to-Revenue Multiple BCAB
General company analysis:BioAtla Corp BCAB
Manufactured products of BioAtla Inc

Forward P/S evaluates market capitalization relative to expected annual revenue, allowing investors to promptly adjust asset valuations between quarterly reports. By analyzing the estimated forward P/S, one can filter out market noise and assess the fair value of BioAtla, Inc. (BCAB), whose growth potential is embedded in unique conditionally active biopharmaceutical technologies for targeted oncology therapy.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring, Inc.)|LIXT: Forward P/S Multiple|Market Cap to Future Revenue Ratio Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Projected Revenue Ratio Cellectar Biosciences|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|CYCC: Forward P/S Multiple|GTHX (G1 Therapeutics) - Price-to-Projected Revenue Ratio|KRON (Kronos Bio Corp) - Forward P/S Multiple|Kintara Pharma (KTRA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Oncternal Therapeutics (ONCT)|PRTG - Market Cap to Future Revenue Ratio